Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R. Evans TRJ, et al. Among authors: ranson m. Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25. Br J Cancer. 2019. PMID: 30679780 Free PMC article. Clinical Trial.
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR. Khan OA, et al. Among authors: ranson m. Br J Cancer. 2008 May 20;98(10):1614-8. doi: 10.1038/sj.bjc.6604366. Epub 2008 May 13. Br J Cancer. 2008. PMID: 18475294 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JHM, Shapiro GI. Boss DS, et al. Among authors: ranson m. Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.
A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
Molife LR, Dean EJ, Blanco-Codesido M, Krebs MG, Brunetto AT, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, Wood K, de Las Heras B, Ranson MR. Molife LR, et al. Among authors: ranson mr. Clin Cancer Res. 2014 Dec 15;20(24):6284-94. doi: 10.1158/1078-0432.CCR-14-0409. Epub 2014 Oct 2. Clin Cancer Res. 2014. PMID: 25278451 Clinical Trial.
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Danson S, et al. Among authors: ranson m. Cancer. 2003 Aug 1;98(3):542-53. doi: 10.1002/cncr.11535. Cancer. 2003. PMID: 12879472 Free article. Clinical Trial.
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP. Ranson M, et al. Clin Cancer Res. 2006 Mar 1;12(5):1577-84. doi: 10.1158/1078-0432.CCR-05-2198. Clin Cancer Res. 2006. PMID: 16533784 Clinical Trial.
IAPs as a target for anticancer therapy.
Danson S, Dean E, Dive C, Ranson M. Danson S, et al. Among authors: ranson m. Curr Cancer Drug Targets. 2007 Dec;7(8):785-94. doi: 10.2174/156800907783220471. Curr Cancer Drug Targets. 2007. PMID: 18220537 Review.
347 results